Business
GeneICE – CRT Research Update
GeneICE – CRT Research Update.
About this update from Valirx Plc
[{"type":"text","content":"\n \nFor immediate release: 17th January 2008\n\n VALIRX PLC \n\n (\"ValiRx\" or the \"Company\") \n\n GeneICE - CRT Research Update \n\n- First Phase of Pre-Clinicals Successfully Completed, Second Phase To Begin - \n\nValiRx (AIM: VAL), the cancer therapeutics company, is pleased to announce that\nfurther to the announcements made on [14] May 2007 and [10] September 2007, its\nsubsidiary, Cronos Therapeutics Ltd (\"Cronos\"), in conjunction with Cancer\nResearch Technology Limited (\"CRT\"), has completed the final part of the first\nphase of pre-clinical studies on one of its cancer therapeutics development\nprogrammes.\n\nUnder this work, the original GeneICE therapeutics molecule researched has\nsuccessfully been shown to trigger cell death in ovarian, pancreatic and\nprostate cancer cells.\n\nAs a result, the development of therapeutic treatments based on this GeneICE\ncompound can now commence; this work is being fully funded by a development\ngrant whereby ValiRx retains all commercial rights. It is anticipated that\nshould this next phase go according to plan, the Company would be in a position\nto begin the regulatory filings in relation to Phase 1 human trials in the\nfourth quarter of 2008.\n\nIn addition, Cronos has expanded its product portfolio with the development of\na second GeneICE molecule, which according to the Company has performed well in\ninitial tests.\n\nDr Satu Vainikka, CEO of ValiRx, commented:\n\n\"We are delighted with the progress being made with CRT. The GeneICE\ntechnology, with its European and US patent rights secured, remains a central\nfocus for the Company and provides the rationale for us developing\ncomplementary diagnostic technologies both in the UK and through our research\nand commercialisation division, ValiBIO S.A., in Belgium. We look forward to\nthe steady development of our R&D programmes in 2008.\"\n\n --Ends-- \n\nInformation on Cancer Research Technology Limited\n\nCRT is a specialist technology transfer company which aims to develop new\ndiscoveries in cancer research for the benefit of cancer patients. CRT is\nwholly owned by Cancer Research UK, the largest independent funder of cancer\nresearch in the world. CRT works closely with leading international cancer\nscientists and their institutes to protect intellectual property arising from\ntheir research and to establish...